Cerveau Technologies has signed an agreement to provide Roche with the PET radiotracer F-18 MK-6240 for assessing the status and progression of tau neurofibrillary tangles (NFTs) in the brain.
Tau protein NFTs are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. F-18 MK-6240 was developed to measure tau levels of PET scans. Roche will use the investigational tracer to help develop potential therapeutic treatments.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
